{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:30:21Z","timestamp":1756384221935,"version":"3.44.0"},"reference-count":16,"publisher":"BMJ","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[2001,7]]},"abstract":"<jats:p>It is estimated that 0.5-1.4% of school-aged children in England and Wales have severe hyperactivity,1<jats:sup>,<\/jats:sup>2 a syndrome characterised by impulsiveness, inattention and overactivity. In the UK, two CNS stimulants, methylphenidate and dexamfetamine (dexamphetamine), are licensed for treating childhood hyperactivity where non-drug measures alone have proved insufficient. In 1995, we concluded that behavioural and educational approaches should be first-choice steps in most children with hyperactivity, with stimulant drugs being reserved for children in whom the disorder is severe or who are resistant to non-drug treatments.2 Here, we reassess the place of stimulant drugs in the management of severe hyperactivity in children.<\/jats:p>","DOI":"10.1136\/dtb.2001.39752","type":"journal-article","created":{"date-parts":[[2008,7,18]],"date-time":"2008-07-18T16:15:40Z","timestamp":1216397740000},"page":"52-54","source":"Crossref","is-referenced-by-count":1,"title":["Stimulant drugs for severe hyperactivity in childhood"],"prefix":"10.1136","volume":"39","member":"239","published-online":{"date-parts":[[2001,7,1]]},"reference":[{"key":"2025082700473672000_39.7.52.1","doi-asserted-by":"crossref","unstructured":"Meltzer H Gatward R . The mental health of children and adolescents in Great Britain London: The Stationery Office 2000.","DOI":"10.1037\/e597192009-001"},{"key":"2025082700473672000_39.7.52.2","first-page":"57","article-title":"The management of hyperactive children","volume-title":"DTB","volume":"33","year":"1995"},{"key":"2025082700473672000_39.7.52.3","unstructured":"The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic criteria for research Geneva: World Health Organization 1993."},{"key":"2025082700473672000_39.7.52.4","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders . Fourth Edition (DSM-IV) Washington DC: American Psychiatric Association 1994."},{"key":"2025082700473672000_39.7.52.5","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s007870050067","article-title":"Clinical guidelines for hyperkinetic disorder","volume":"7","author":"Taylor","year":"1998","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"2025082700473672000_39.7.52.6","unstructured":"McMaster University Evidence-Based Practice Center. Treatment of Attention-Deficit\/Hyperactivity Disorder (AHCPR No. 00-E005) . An Evidence Report\/Technology Assessment No.11 Washington DC: US Agency for Health Care Policy and Research 1999."},{"key":"2025082700473672000_39.7.52.7","unstructured":"Miller A Lee SK Raina P Klassen A Zupancic J Olsen L . A review of therapies for attention-deficit\/hyperactivity disorder Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 1998."},{"key":"2025082700473672000_39.7.52.8","first-page":"1073","article-title":"A 14-month randomized clinical trial of treatment strategies for attention-deficit\/hyperactivity disorder","volume-title":"Arch Gen Psychiatry","volume":"56","author":"MTA Cooperative Group","year":"1999"},{"key":"2025082700473672000_39.7.52.9","unstructured":"Equasym Summary of product characteristics, UK Medeva Pharma Ltd November 2000."},{"key":"2025082700473672000_39.7.52.10","unstructured":"Ritalin Summary of product characteristics, UK Novartis Pharmaceuticals UK Ltd October 2000."},{"key":"2025082700473672000_39.7.52.11","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1001\/jama.279.14.1100","article-title":"Diagnosis and treatment of attention-deficit\/hyperactivity disorder in children and adolescents","volume":"279","author":"Goldman","year":"1998","journal-title":"JAMA"},{"key":"2025082700473672000_39.7.52.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.14.1100"},{"key":"2025082700473672000_39.7.52.13","unstructured":"Attention Deficit and Hyperkinetic Disorders in Children and Young People SIGN Publication number 52 (2001). Scottish Intercollegiate Guidelines Network. http:\/\/www.sign.ac.uk [June 2001]."},{"key":"2025082700473672000_39.7.52.14","unstructured":"National Institute for Clinical Excellence. Guidance on the use of methylphenidate (Ritalin, Equasym) for Attention Deficit\/Hyperactivity Disorder (ADHD) in childhood Technology Appraisal Guidance No. 13. http:\/\/www.nice.org.uk [October 2000]."},{"key":"2025082700473672000_39.7.52.15","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/adc.84.5.404","article-title":"An auditable protocol for treating attention deficit\/hyperactivity disorder","volume":"84","author":"Hill","year":"2001","journal-title":"Arch Dis Child"},{"key":"2025082700473672000_39.7.52.16","unstructured":"Dexedrine Summary of product characteristics, UK Medeva Pharma Ltd March 2000."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2001.39752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:47:43Z","timestamp":1756280863000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2001.39752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":16,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2001,7,1]]},"published-print":{"date-parts":[[2001,7]]}},"alternative-id":["10.1136\/dtb.2001.39752"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2001.39752","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}